丙型肝炎病毒清除对HIV/HCV合并感染者骨密度的影响
本研究前瞻性纳入238例HIV/HCV合并感染者,评估抗HCV治疗后96周骨密度及骨重塑标志物的变化。结果显示,获得持续病毒学应答(SVR)与腰椎和股骨颈标准化骨密度(sBMD)及sRANKL、OPG水平的变化均无显著关联。
要点
- HIV/HCV合并感染者基线腰椎骨质疏松患病率为17.6%,股骨颈为7.2%。
核心结论
- 在HIV/HCV合并感染者中,获得持续病毒学应答(SVR)与骨密度及骨重塑标志物的显著变化无关。
研究设计与样本
- 前瞻性研究,纳入238例HIV/HCV合并感染者,评估基线及96周时腰椎和股骨颈标准化骨密度(sBMD)、WHO骨密度分类及血浆sRANKL和OPG浓度。
主要发现
- 基线时腰椎和股骨颈骨质疏松患病率分别为17.6%和7.2%。
- 基线及第96周时,瞬时弹性成像所测纤维化与腰椎和股骨颈sBMD均无显著相关性。
临床怎么用
- 对于HIV/HCV合并感染者,不应仅因获得SVR而预期骨密度改善,仍需按常规评估和管理骨健康。
局限性
- 原文未明确报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Little is known about the effects of eradication of hepatitis C virus (HCV) on bone mineral density (BMD) and biomarkers of bone remodeling in human immunodeficiency virus (HIV)/HCV-coinfected patients. METHODS: We prospectively assessed standardized BMD (sBMD) at the lumbar spine and femoral neck, World Health Organization BMD categories at both sites, and plasma concentrations of soluble receptor activator of NF-κβ ligand (sRANKL), and osteoprotegerin (OPG) at baseline (the date of initiation of anti-HCV therapy) and at 96 weeks. RESULTS: A total of 238 patients were included. The median age was 49.5 years, 76.5% were males, 48.3% had cirrhosis, 98.3% were on antiretroviral therapy, median CD4+ cell count was 527 cells/μL, and 86.6% had HIV-1 RNA <50 copies/mL. The prevalence of osteoporosis at baseline at the lumbar spine (LS) and femoral neck (FN) was 17.6% and 7.2%, respectively. Anti-HCV therapy comprised pegylated interferon (peg-IFN) and ribavirin (RBV) plus 1 direct-acting antiviral in 53.4%, peg-IFN/RBV in 34.5%, and sofosbuvir/RBV in 12.2%. A total of 145 (60.9%) patients achieved sustained virologic response (SVR). No significant effect of SVR was observed on sBMD for the interaction between time and SVR either in the LS (P = .801) or the FN (P = .911). Likewise, no significant effect of SVR was observed in plasma levels of sRANKL (P = .205), OPG (P = .249), or sRANKL/OPG ratio (P = .123) for the interaction between time and SVR. No significant correlation was found between fibrosis by transient elastography, and LS and FN sBMD, at baseline and week 96. CONCLUSIONS: SVR was not associated with significant changes in BMD nor biomarkers of bone remodeling in HIV/HCV-coinfected persons.
引用
- Carrero A, Berenguer J, Hontañón V, et al. Effects of Hepatitis C Virus (HCV) Eradication on Bone Mineral Density in Human Immunodeficiency Virus/HCV-Coinfected Patients. Clin Infect Dis. 2021. PMID: 32930720. doi:10.1093/cid/ciaa1396
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。